Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety an...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5ea2556c1e334f54ba7405a536fac57e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day.Methods: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded.Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.Keywords: Cosopt, timolol, dorzolamide, glaucoma, intraocular pressure, dosage |
|---|